Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

Blood Neoplasia 2026 Open access

Read full text
Authors: Christoph Weigel, Haley Klimaszewski, Fode Tounkara, Selamawit Addissie, Sarah Schlotter, Betsy Pray, James P. Dugan, Bradley M. Haverkos, Lynda Villagomez, Mark Lustberg, Pierluigi Porcu, Timothy Voorhees
+9 more Richard F. Ambinder, Shannon C. Kenney, Joyce Fingeroth, Henri‐Jacques Delecluse, Michael A. Caligiuri, Lapo Alinari, Ginny L. Bumgardner, Christopher C. Oakes, Robert A. Baiocchi
DOI: 10.1016/j.bneo.2026.100200
Cited by: 3
References: 51

Abstract

expression in CNSL via locus-specific promoter activation, which may hold value for determining GARD sensitivity.

Fields of Study & Subjects

Viral-associated cancers and disorders Cytomegalovirus and herpesvirus research interferon and immune responses

Publication details

Journal / source
Blood Neoplasia
Publisher
Elsevier BV
Volume
3
Issue
2
Pages
100200–100200
Publication date
28 January 2026
Language
EN